Τwo-panel molecular testing for genetic predisposition for thrombosis using multi-allele visual biosensors

Analytical and Bioanalytical Chemistry
Nikolaos FountoglouPenelope C Ioannou

Abstract

Thrombosis is considered as the most typical example of multigenic/multifactorial disorder. The three most common genetic risk factors for thrombotic disorders are the G1691A mutation in factor V gene (FV Leiden), the G20210Α mutation in prothrombin gene (FII), and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene. An additional panel of biomarkers predisposing for thrombotic events includes the H1299R variant in factor V gene (HR2), A1298C variant in MTHFR gene, the V34L mutation in fibrinogen stabilizing factor XIII (FXIII) gene as well as the 4G/5G polymorphism in plasminogen activator inhibitor type-1 (PAI-1) gene. In this context, we report a novel, rapid and low-cost two-panel diagnostic platform for the simultaneous visual genotyping of the seven mutations (14 alleles). The proposed method comprises the following: (a) a multiplex PCR using genomic DNA isolated from peripheral blood, (b) a multiplex genotyping reaction based on allele-specific primer extension, and (c) visual detection of the genotyping reaction products by means of a multi-allele dipstick-type DNA biosensor, using gold nanoparticles as reporters. The method was applied to 40, previously characterized, and 15 blind clinical sample...Continue Reading

References

Jun 27, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·B Schwahn, R Rozen
Jan 2, 2007·Analytical Biochemistry·Despina P KalogianniElias Panagiotopoulos
Oct 8, 2008·Methods in Molecular Biology·Susan Bortolin
Jan 27, 2009·Current Protocols in Human Genetics·Stacey GabrielDiana Tabbaa
Sep 22, 2009·Methods in Molecular Biology·Muriel GaudetMaurizio Sabatti
Jul 20, 2010·Biosensors & Bioelectronics·Maria A VlachouGeorgios Vartholomatos
Mar 11, 2011·Nanotechnology·Dimitrios S ElenisTheodore K Christopoulos

❮ Previous
Next ❯

Citations

Nov 29, 2017·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ahmed AmaraBrahim Nsiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Related Papers

Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Maria AmvrosiadouPenelope C Ioannou
Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Fabio L LinoRosiane Mattar
© 2022 Meta ULC. All rights reserved